This clinical trial will determine whether taking ascorbic acid (vitamin C), α-tocopherol (vitamin E), or both together can lower markers of brain inflammation and change the expression of neuropeptides in Mexican adults with obesity.
Main Questions
The study aims to answer:
1. Does vitamin C, vitamin E, or both reduce neuroinflammation? 2. Do these supplements change the expression of neuropeptides linked to obesity? Comparison Groups Researchers will compare the effects of vitamin C alone, vitamin E alone, and the combination of both to see if they improve brain health in people with obesity.
What Participants Will Do
Participants will:
1. Take vitamin C, vitamin E, or both daily, depending on their assigned group 2. Attend clinic visits once every 2 weeks for and tests for checkups and tests for record and report supplement intake so that researchers can monitor and evaluate treatment adherence 3. Provide samples and health information to measure inflammation and neuropeptides , at the beginning of the intervention and at 12 weeks, when the intervention ends.
Adults aged 40 to 59 years, Mexican men and women.
Obese group: Body mass index (BMI) > 30 kg/m²; body fat percentage > 25% in men and > 35% in women; waist circumference > 90 cm in men and > 80 cm in women.
Non-obese group: BMI < 24.9 kg/m²; body fat percentage < 25% in men and < 35% in women; waist circumference < 90 cm in men and < 80 cm in women.
Willingness to sign the informed consent form.
Individuals with renal diseases, hepatic diseases, or those under pharmacological treatment for any condition associated with acute inflammation.
Individuals currently undergoing treatment for obesity (pharmacological, nutritional, or physical activity programs).
Individuals taking dietary supplements or multivitamins.
Parallel
Ascorbic acid (Vitamin C)
Dietary supplementParticipants will receive 1000 mg of ascorbic acid orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect of ascorbic acid supplementation in the Biomarkers of neuroinflammation and neuropeptide expression
tocopherol alpha
Dietary supplementParticipants will receive 800 mg of tocopherol orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect of tocopherol supplementation in the Biomarkers of neuroinflammation and neuropeptide expression
Ascorbic acid + tocopherol alpha
Combination productParticipants will receive 1000mg of ascorbic acid + 800 mg of tocopherol orally once daily for 12 weeks. The intervention is administered in tablet form and aims to evaluate the therapeutic effect ofsupplementation in the Biomarkers of neuroinflammation and neuropeptide expression
decrese expression of neuroinflammation biomarkers
Variation in the expression levels of pro-inflammatory cytokines (IL-1β, TNF-α, IL-8) and glial activation proteins (GFAP, S100B) will be assessed as indicators of neuroinflammatory processes.
Change in neuropeptide expression levels
Variation in the expression levels of neuropeptides NPY/AgRP and POMC will be assessed as indicators of hypothalamic regulation of appetite and energy balance.
Change in metabolic parameters
Variation in body mass index (BMI), fasting glucose and lipid profile
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
